Skip to main content
Oramed Pharmaceuticals Inc. logo

Oramed Pharmaceuticals Inc. — Investor Relations & Filings

Ticker · ORMP ISIN · US68403P2039 LEI · 5299006K52ZIIGQJ6R84 TA Manufacturing
Open in API
Filings indexed 1,576 across all filing types
Latest filing 2023-01-12 Regulatory Filings
Country US United States of America
Listing TA ORMP

About Oramed Pharmaceuticals Inc.

https://www.oramed.com

Oramed Pharmaceuticals Inc. is a clinical-stage company focused on developing oral drug delivery systems for medications that are typically administered via injection. The company's core technology is its proprietary Protein Oral Delivery (POD™) platform, which is designed to protect therapeutic proteins from enzymatic degradation in the gastrointestinal tract and enhance their absorption into the bloodstream. Oramed's lead product candidate is an oral insulin capsule (ORMD-0801) for the treatment of diabetes. The company's pipeline also includes an oral GLP-1 analog capsule (ORMD-0901) for type 2 diabetes. Oramed aims to improve patient compliance, comfort, and therapeutic outcomes by converting injectable treatments into oral formulations.

Recent filings

Filing Released Lang Actions
Form 8-K - Phase 3 Results
Regulatory Filings Classification · 98% confidence The document explicitly identifies itself as a "FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934." Form 8-K is used to announce major events that shareholders should know about between required periodic filings (like 10-K or IR). Item 8.01, 'Other Events,' details the announcement of disappointing Phase 3 clinical trial results for ORMP-0801 and the subsequent decision to discontinue oral insulin clinical activities for T2D. Since Form 8-K is a mandatory, specific SEC filing for material current events and does not fit the definitions for 10-K (Annual Report), IR (Interim Report), or ER (Earnings Release), the most appropriate classification among the provided options is the general regulatory filing category, RNS (Regulatory Filings), as it represents a required, non-periodic disclosure to the market. Although it is a specific SEC form, RNS serves as the best fit for miscellaneous, mandatory regulatory announcements not covered by the other specific codes.
2023-01-12 English
Form 8-K - Phase 3 Results
Report Publication Announcement Classification · 98% confidence The document is very short (1863 characters) and explicitly states, "Attached hereto is a report on *Form 8-K - Phase 3 Results*" followed by a PDF filename. This structure indicates that the document itself is an announcement about the publication of another report (Form 8-K), rather than the full content of the Form 8-K or the underlying financial results. According to Rule 2 ('MENU VS MEAL' Rule), when a document announces the publication of a report, it should be classified as a Report Publication Announcement (RPA). Since this is a regulatory filing announcing results, RPA is the most appropriate specific category, although RNS is a possible fallback if RPA didn't exist.
2023-01-12 English
CURRENT REPORT
Regulatory Filings
2023-01-11 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Rabinowitz Michael
Director's Dealing Classification · 98% confidence The document is explicitly titled "FORM 4" and references the "UNITED STATES SECURITIES AND EXCHANGE COMMISSION" and "Section 16(a) of the Securities Exchange Act of 1934". Form 4 is the standard SEC filing used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (insider trades). Although the filing is related to insider transactions, the provided classification options do not have a specific code for SEC Form 4. The closest fit among the provided codes is 'Director's Dealing' (DIRS), which covers 'Report of personal share transactions by company directors and executives (insider trades)'. The document details transactions (Acquired/Disposed of) by Michael Rabinowitz, the Chief Commercial Officer.
2023-01-04 English
FORM 4-STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES -Rabinowitz Michael
Director's Dealing Classification · 98% confidence The document explicitly states it is attaching a report on "Form 4 - Michael Rabinowitz". Form 4 filings in the US regulatory context (mentioned via NASDAQ CM and US Securities Laws) are used to report changes in beneficial ownership of securities by company insiders (directors, officers, or 10% owners). This directly corresponds to the definition of Director's Dealing (insider trades). The document is short (1881 chars) and announces the attachment of a specific form, which aligns with the 'Menu vs Meal' rule suggesting an announcement, but the specific nature of Form 4 points strongly to the 'Director's Dealing' category (DIRS) rather than a general 'Report Publication Announcement' (RPA) or 'Regulatory Filing' (RNS), as DIRS is a more specific classification for insider transaction reports.
2023-01-04 English
FORM 4 SUBMISSION
Director's Dealing
2023-01-04 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.